Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 92Triple Negative Breast Neoplasms 39Neoplasm Metastasis 12Carcinoma, Non-Small-Cell Lung 10Neoplasms 8Stomach Neoplasms 6Pancreatic Neoplasms 6Ovarian Neoplasms 6Colorectal Neoplasms 6Melanoma 5Cholangiocarcinoma 5Sarcoma 4Prostatic Neoplasms 4Lung Neoplasms 4Inflammatory Breast Neoplasms 4Breast Neoplasms, Male 4Brain Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Small Cell Lung Carcinoma 3Gallbladder Neoplasms 3Esophageal Neoplasms 3Endometrial Neoplasms 3Colonic Neoplasms 3Carcinoma, Hepatocellular 3Carcinoma, Ductal, Breast 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Mesothelioma, Malignant 2Mesothelioma 2Lymphoma, Non-Hodgkin 2

Interventions

adavosertib 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Triple-negative Metastatic Breast Cancer × Cisplatin × Breast × Clear all
NCT03012477 2021-11-23

CISPLATIN + AZD-1775 In Breast Cancer

Dana-Farber Cancer Institute

Phase 2 Completed
34 enrolled 9 charts
Breast

Triple-negative Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡